

Benoît Ranchoux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3208027/publications.pdf>

Version: 2024-02-01

28
papers

1,673
citations

471509

17
h-index

752698

20
g-index

29
all docs

29
docs citations

29
times ranked

2530
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Human and Experimental Pulmonary Veno-Occlusive Disease. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 118-131.	2.9	24
2	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. , 2020, , 63-70.		2
3	Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease. Circulation Research, 2019, 125, 449-466.	4.5	73
4	The BET Bromodomain Inhibitor I-BET-151 Induces Structural and Functional Alterations of the Heart Mitochondria in Healthy Male Mice and Rats. International Journal of Molecular Sciences, 2019, 20, 1527.	4.1	17
5	Enhanced Pulmonary Artery Radiodensity in Pulmonary Arterial Hypertension: A Sign of Early Calcification?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 799-802.	5.6	6
6	Late Breaking Abstract - Inflammation and metabolic syndrome exacerbate pulmonary hypertension associated with left heart disease. , 2019, , .		0
7	NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension. Circulation, 2018, 137, 2371-2389.	1.6	75
8	Sirtuin 1 regulates pulmonary artery smooth muscle cell proliferation. Journal of Hypertension, 2018, 36, 1164-1177.	0.5	48
9	Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover) Tj ETQq1 1 0.784314 rgBT /Overlock 115	1.7	115
10	FOXO1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension. Journal of Molecular Medicine, 2018, 96, 223-235.	3.9	62
11	NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension. , 2018, , .		0
12	Fine structural modifications of heparan sulfate sulfation patterns in lung are associated with functional effects in Precapillary Pulmonary Hypertension. , 2018, , .		0
13	Gutâ€“Lung Connection in Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 402-405.	2.9	34
14	Bacterial translocation in pulmonary hypertension. , 2017, , .		0
15	DNA Damage and Pulmonary Hypertension. International Journal of Molecular Sciences, 2016, 17, 990.	4.1	85
16	Response to Letter Regarding Article, â€œMitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Modelâ€• Circulation, 2016, 133, e592-3.	1.6	4
17	MicroRNA networks in pulmonary arterial hypertension. Current Opinion in Oncology, 2016, 28, 72-82.	2.4	27
18	Potassium Channel Subfamily K Member 3 (KCNK3) Contributes to the Development of Pulmonary Arterial Hypertension. Circulation, 2016, 133, 1371-1385.	1.6	141

#	ARTICLE	IF	CITATIONS
19	Nebivolol for Improving Endothelial Dysfunction, Pulmonary Vascular Remodeling, and Right Heart Function in Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2015, 65, 668-680.	2.8	119
20	Chemotherapy-Induced Pulmonary Hypertension. <i>American Journal of Pathology</i> , 2015, 185, 356-371.	3.8	149
21	Endothelial-to-Mesenchymal Transition in Pulmonary Hypertension. <i>Circulation</i> , 2015, 131, 1006-1018.	1.6	441
22	Mitomycin-Induced Pulmonary Veno-Occlusive Disease. <i>Circulation</i> , 2015, 132, 834-847.	1.6	103
23	miR-223 reverses experimental pulmonary arterial hypertension. <i>American Journal of Physiology - Cell Physiology</i> , 2015, 309, C363-C372.	4.6	103
24	LSC Abstract "Glutamatergic signaling through pulmonary vascular NMDA receptors in pulmonary hypertension." , 2015, , .		0
25	Mitomycin-induced pulmonary veno-occlusive disease: Experience from the French pulmonary hypertension network. , 2015, , .		0
26	Chemotherapy-induced pulmonary hypertension: Role of alkylating agents. , 2015, , .		3
27	CXCL13 in Tertiary Lymphoid Tissues: Sites of Production Are Different from Sites of Functional Localization. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 369-370.	5.6	4
28	N-acetylcysteine improves established monocrotaline-induced pulmonary hypertension in rats. <i>Respiratory Research</i> , 2014, 15, 65.	3.6	38